A new trading day began on Monday, with Edgewise Therapeutics Inc (NASDAQ: EWTX) stock price up 7.97% from the previous day of trading, before settling in for the closing price of $11.42. EWTX’s price has ranged from $10.60 to $38.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -28.55%. With a float of $73.99 million, this company’s outstanding shares have now reached $94.84 million.
In an organization with 110 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Edgewise Therapeutics Inc is 29.63%, while institutional ownership is 71.34%. The most recent insider transaction that took place on Apr 03 ’25, was worth 10,000,000. In this transaction Director of this company bought 496,771 shares at a rate of $20.13, taking the stock ownership to the 14,809,075 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Director bought 496,771 for $20.13, making the entire transaction worth $10,000,000. This insider now owns 14,809,075 shares in total.
Edgewise Therapeutics Inc (EWTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.71% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
Here are Edgewise Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 19.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.05 million. That was better than the volume of 1.65 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 15.31%. Additionally, its Average True Range was 2.04.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 6.95%, which indicates a significant decrease from 11.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 144.86% in the past 14 days, which was higher than the 82.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.31, while its 200-day Moving Average is $25.26. However, in the short run, Edgewise Therapeutics Inc’s stock first resistance to watch stands at $12.73. Second resistance stands at $13.12. The third major resistance level sits at $13.74. If the price goes on to break the first support level at $11.72, it is likely to go to the next support level at $11.10. Assuming the price breaks the second support level, the third support level stands at $10.71.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
With a market capitalization of 1.30 billion, the company has a total of 104,774K Shares Outstanding. Currently, annual sales are 0 K while annual income is -133,810 K. The company’s previous quarter sales were 0 K while its latest quarter income was -39,660 K.
